PH26424A - Platinum pharmaceutical agents - Google Patents

Platinum pharmaceutical agents Download PDF

Info

Publication number: PH26424A
Authority: PH; Philippines
Prior art keywords: compound; platinum; formula; alkyl; mono
Prior art date: 1989-01-17

Application number

PH39898A

Other languages

English (en)

Inventor

Abdolhossen Talebian

Dianna C Green

Philip S Schein

Original Assignee

Univ Georgetown

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-01-17

Filing date

1990-01-16

Publication date

1992-07-15

1990-01-16 Application filed by Univ Georgetown filed Critical Univ Georgetown

1992-07-15 Publication of PH26424A publication Critical patent/PH26424A/en

Links

BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims description 56
229910052697 platinum Inorganic materials 0.000 title description 23
239000008177 pharmaceutical agent Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 190
239000000203 mixture Substances 0.000 claims description 70
229910052757 nitrogen Inorganic materials 0.000 claims description 42
150000002016 disaccharides Chemical class 0.000 claims description 39
125000000217 alkyl group Chemical group 0.000 claims description 26
229910052739 hydrogen Inorganic materials 0.000 claims description 26
HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 23
239000001257 hydrogen Substances 0.000 claims description 22
125000001483 monosaccharide substituent group Chemical group 0.000 claims description 22
125000004432 carbon atom Chemical group C* 0.000 claims description 21
238000000034 method Methods 0.000 claims description 20
150000002772 monosaccharides Chemical class 0.000 claims description 18
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
206010028980 Neoplasm Diseases 0.000 claims description 6
125000003118 aryl group Chemical group 0.000 claims description 5
125000002619 bicyclic group Chemical group 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
150000002431 hydrogen Chemical class 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 4
125000001841 imino group Chemical group [H]N=* 0.000 claims description 3
125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
125000002947 alkylene group Chemical group 0.000 claims 3
229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
150000003058 platinum compounds Chemical class 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 69
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
239000000243 solution Substances 0.000 description 40
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
239000002552 dosage form Substances 0.000 description 36
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 33
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 31
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
239000008103 glucose Substances 0.000 description 25
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
229940093499 ethyl acetate Drugs 0.000 description 24
235000019439 ethyl acetate Nutrition 0.000 description 24
238000001990 intravenous administration Methods 0.000 description 24
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 23
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 21
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 21
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 21
239000000706 filtrate Substances 0.000 description 21
229930182830 galactose Natural products 0.000 description 21
238000007912 intraperitoneal administration Methods 0.000 description 18
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 17
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 16
229960002442 glucosamine Drugs 0.000 description 16
238000007918 intramuscular administration Methods 0.000 description 16
239000000047 product Substances 0.000 description 16
239000000644 isotonic solution Substances 0.000 description 15
239000002244 precipitate Substances 0.000 description 15
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
239000004480 active ingredient Substances 0.000 description 14
150000001720 carbohydrates Chemical class 0.000 description 14
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
206010033128 Ovarian cancer Diseases 0.000 description 13
206010061535 Ovarian neoplasm Diseases 0.000 description 13
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 13
RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 13
229910001863 barium hydroxide Inorganic materials 0.000 description 13
201000010536 head and neck cancer Diseases 0.000 description 13
208000014829 head and neck neoplasm Diseases 0.000 description 13
125000001424 substituent group Chemical group 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
208000024313 Testicular Neoplasms Diseases 0.000 description 12
206010057644 Testis cancer Diseases 0.000 description 12
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 12
239000002253 acid Substances 0.000 description 12
239000000969 carrier Substances 0.000 description 12
208000029742 colonic neoplasm Diseases 0.000 description 12
238000001704 evaporation Methods 0.000 description 12
230000008020 evaporation Effects 0.000 description 12
239000000546 pharmaceutical excipient Substances 0.000 description 12
201000003120 testicular cancer Diseases 0.000 description 12
238000004809 thin layer chromatography Methods 0.000 description 12
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 11
230000008034 disappearance Effects 0.000 description 11
150000002540 isothiocyanates Chemical class 0.000 description 11
229960004316 cisplatin Drugs 0.000 description 10
239000003937 drug carrier Substances 0.000 description 10
229940035423 ethyl ether Drugs 0.000 description 10
238000001953 recrystallisation Methods 0.000 description 10
241000699670 Mus sp. Species 0.000 description 9
-1 N-acetylamino Chemical group 0.000 description 9
230000001093 anti-cancer Effects 0.000 description 9
230000004083 survival effect Effects 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 8
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
150000007513 acids Chemical class 0.000 description 8
239000000945 filler Substances 0.000 description 8
239000004615 ingredient Substances 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
208000032839 leukemia Diseases 0.000 description 8
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
230000000704 physical effect Effects 0.000 description 8
125000003132 pyranosyl group Chemical group 0.000 description 8
239000003826 tablet Substances 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 7
239000006186 oral dosage form Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000011734 sodium Substances 0.000 description 7
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
241001529936 Murinae Species 0.000 description 6
239000001863 hydroxypropyl cellulose Substances 0.000 description 6
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
239000012299 nitrogen atmosphere Substances 0.000 description 6
229910052717 sulfur Inorganic materials 0.000 description 6
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
150000008266 deoxy sugars Chemical class 0.000 description 5
239000003814 drug Substances 0.000 description 5
229930182470 glycoside Chemical group 0.000 description 5
150000002338 glycosides Chemical group 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
150000005846 sugar alcohols Chemical class 0.000 description 5
230000003442 weekly effect Effects 0.000 description 5
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 4
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
229920000623 Cellulose acetate phthalate Polymers 0.000 description 4
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 4
HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 4
ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 4
ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 4
ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 4
239000001856 Ethyl cellulose Substances 0.000 description 4
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
229930091371 Fructose Natural products 0.000 description 4
239000005715 Fructose Substances 0.000 description 4
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 4
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 4
HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
229910052788 barium Inorganic materials 0.000 description 4
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 4
235000013871 bee wax Nutrition 0.000 description 4
239000012166 beeswax Substances 0.000 description 4
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 4
239000007894 caplet Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000004203 carnauba wax Substances 0.000 description 4
235000013869 carnauba wax Nutrition 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229940081734 cellulose acetate phthalate Drugs 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 4
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000000921 elemental analysis Methods 0.000 description 4
235000019325 ethyl cellulose Nutrition 0.000 description 4
229920001249 ethyl cellulose Polymers 0.000 description 4
STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 4
230000037406 food intake Effects 0.000 description 4
125000003843 furanosyl group Chemical group 0.000 description 4
125000000623 heterocyclic group Chemical group 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
229940060367 inert ingredients Drugs 0.000 description 4
239000006204 intramuscular dosage form Substances 0.000 description 4
239000006206 intraperitoneal dosage form Substances 0.000 description 4
239000006207 intravenous dosage form Substances 0.000 description 4
DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000003446 ligand Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
150000002734 metacrylic acid derivatives Chemical class 0.000 description 4
229920000609 methyl cellulose Polymers 0.000 description 4
239000001923 methylcellulose Substances 0.000 description 4
235000010981 methylcellulose Nutrition 0.000 description 4
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
235000021317 phosphate Nutrition 0.000 description 4
150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
229920000193 polymethacrylate Polymers 0.000 description 4
229920000915 polyvinyl chloride Polymers 0.000 description 4
239000004800 polyvinyl chloride Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
239000011593 sulfur Substances 0.000 description 4
150000003467 sulfuric acid derivatives Chemical class 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
239000001993 wax Substances 0.000 description 4
DDHUNHGZUHZNKB-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diamine Chemical compound NCC(C)(C)CN DDHUNHGZUHZNKB-UHFFFAOYSA-N 0.000 description 3
CLOSFPUIYFHGPR-UHFFFAOYSA-L 2-acetamidopropanedioate;barium(2+) Chemical compound [Ba+2].CC(=O)NC(C([O-])=O)C([O-])=O CLOSFPUIYFHGPR-UHFFFAOYSA-L 0.000 description 3
DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
PNMDNJALVHCMOX-AVBXVCIKSA-N [(2r,3s,4r,5r)-5-acetamido-3,4-diacetyloxy-6-isothiocyanatooxan-2-yl]methyl acetate Chemical compound CC(=O)N[C@H]1C(N=C=S)O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O PNMDNJALVHCMOX-AVBXVCIKSA-N 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000008112 carboxymethyl-cellulose Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
125000000896 monocarboxylic acid group Chemical group 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
238000005406 washing Methods 0.000 description 3
238000011765 DBA/2 mouse Methods 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
DFUVZQDRDFOOCF-UHFFFAOYSA-L [Ba+2].[O-]C(=O)C(C([O-])=O)NC=O Chemical compound [Ba+2].[O-]C(=O)C(C([O-])=O)NC=O DFUVZQDRDFOOCF-UHFFFAOYSA-L 0.000 description 2
230000000719 anti-leukaemic effect Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
238000002513 implantation Methods 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
QLTGEMIEWNAURK-DKWTVANSSA-L (2s)-2-aminobutanedioate;barium(2+) Chemical compound [Ba+2].[O-]C(=O)[C@@H](N)CC([O-])=O QLTGEMIEWNAURK-DKWTVANSSA-L 0.000 description 1
YWNNXTFWQRXKOO-UBRBJVMESA-N 2-[[(3R,4R,5S,6R)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]amino]-2-(carboxymethylamino)-3-sulfanylidenepropanoic acid Chemical compound C(C)(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1OC(C)=O)OC(C)=O)COC(C)=O)NC(C(=O)O)(NCC(=O)O)C=S YWNNXTFWQRXKOO-UBRBJVMESA-N 0.000 description 1
FPYRGBGIXXZJDX-UHFFFAOYSA-N 2-acetamidopropanedioic acid;barium Chemical compound [Ba].CC(=O)NC(C(O)=O)C(O)=O FPYRGBGIXXZJDX-UHFFFAOYSA-N 0.000 description 1
LVEGZFXIIKKYTA-UHFFFAOYSA-N 2-iminopropanedioic acid Chemical compound OC(=O)C(=N)C(O)=O LVEGZFXIIKKYTA-UHFFFAOYSA-N 0.000 description 1
WLEHEWWMHHJASO-UHFFFAOYSA-N 4-aminocyclohexane-1,1-dicarboxylic acid Chemical compound NC1CCC(C(O)=O)(C(O)=O)CC1 WLEHEWWMHHJASO-UHFFFAOYSA-N 0.000 description 1
101710134784 Agnoprotein Proteins 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
CWZMTPMBINXCIA-CMSCEZBTSA-N C(C)(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1OC(C)=O)OC(C)=O)COC(C)=O)C(C(=O)O)NC(C(=O)O)(C=S)N Chemical compound C(C)(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1OC(C)=O)OC(C)=O)COC(C)=O)C(C(=O)O)NC(C(=O)O)(C=S)N CWZMTPMBINXCIA-CMSCEZBTSA-N 0.000 description 1
101100522123 Caenorhabditis elegans ptc-1 gene Proteins 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229910021607 Silver chloride Inorganic materials 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
150000001553 barium compounds Chemical class 0.000 description 1
239000003637 basic solution Substances 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000001273 butane Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
ISOLMABRZPQKOV-UHFFFAOYSA-N diethyl 2-acetamidopropanedioate Chemical compound CCOC(=O)C(NC(C)=O)C(=O)OCC ISOLMABRZPQKOV-UHFFFAOYSA-N 0.000 description 1
125000000600 disaccharide group Chemical group 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229950006191 gluconic acid Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
ZVYNEIVHNNYCSE-UHFFFAOYSA-N piperidine-4,4-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCNCC1 ZVYNEIVHNNYCSE-UHFFFAOYSA-N 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
239000000376 reactant Substances 0.000 description 1
HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
229910000367 silver sulfate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000005156 substituted alkylene group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229960005137 succinic acid Drugs 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002381 testicular Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)

PH39898A 1989-01-17 1990-01-16 Platinum pharmaceutical agents PH26424A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29736889A	1989-01-17	1989-01-17
US07/301,773 US4946954A (en)	1989-01-17	1989-01-26	Platinum pharmaceutical agents

Publications (1)

Publication Number	Publication Date
PH26424A true PH26424A (en)	1992-07-15

Family

ID=26970120

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH39898A PH26424A (en)	1989-01-17	1990-01-16	Platinum pharmaceutical agents

Country Status (13)

Country	Link
US (1)	US4946954A (de)
EP (1)	EP0462980A4 (de)
JP (1)	JP2771326B2 (de)
AU (2)	AU5039490A (de)
CA (1)	CA2045120A1 (de)
HU (1)	HUT59690A (de)
IL (1)	IL93090A (de)
NO (1)	NO180588C (de)
NZ (1)	NZ232134A (de)
PH (1)	PH26424A (de)
RU (1)	RU2074861C1 (de)
WO (1)	WO1990008157A1 (de)
ZA (1)	ZA90336B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5041581A (en) *	1985-10-18	1991-08-20	The University Of Texas System Board Of Regents	Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5384127A (en) *	1985-10-18	1995-01-24	Board Of Regents, The University Of Texas System	Stable liposomal formulations of lipophilic platinum compounds
AU614901B2 (en) *	1989-04-04	1991-09-12	Daikin Industries, Ltd.	New fluorocarbon platinum complexes
US5871710A (en) *	1992-09-04	1999-02-16	The General Hospital Corporation	Graft co-polymer adducts of platinum (II) compounds
WO1996000079A1 (en) *	1994-06-27	1996-01-04	The General Hospital Corporation	Graft co-polymer adducts of platinum (ii) compounds
NZ307633A (en) *	1995-05-09	2000-01-28	Kreatech Biotechnology Bv	Methods for the production of platinum-based linkers between labels and bio-organic molecules, for labelling bio-organic molecules, for detecting
US5843475A (en) *	1996-12-06	1998-12-01	Board Of Regents, The University Of Texas System	Delivery and activation through liposome incorporation of diaminocyclohexane platinum (II) complexes
US6235776B1 (en)	1998-11-12	2001-05-22	Cell Pathways, Inc.	Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
US6235782B1 (en)	1998-11-12	2001-05-22	Rifat Pamukcu	Method for treating a patient with neoplasia by treatment with a platinum coordination complex
JP4776843B2 (ja)	1999-10-01	2011-09-21	イムノゲンインコーポレーティッド	免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
AU2006222657B2 (en) *	2000-01-04	2009-01-15	Access Pharmaceuticals, Inc.	N,O-amidomalonate platinum complexes
US7166733B2 (en) *	2000-01-04	2007-01-23	Access Pharmaceuticals, Inc.	O,O'-Amidomalonate and N,O-Amidomalonate platinum complexes
CA2396702C (en) *	2000-01-04	2010-03-23	Access Pharmaceuticals, Inc.	N,o-amidomalonate platinum complexes
RU2219183C2 (ru) *	2000-03-03	2003-12-20	Зукин ЯН	Производное комплекса удвоенная дикарбоновая кислота-диаминоплатина, способ его получения, противоопухолевая фармацевтическая композиция и использование этого производного
KR20040074857A (ko) *	2003-02-19	2004-08-26	학교법인 이화학당	Ｎ-치환 아미노디카복실산의 백금(ⅱ) 착물 및 그 제조방법
JP2006521300A (ja) *	2003-03-31	2006-09-21	プリヴァ−ラケマ，エー．エス．	活性物質として白金錯体を含有する医薬組成物およびその製造方法
KR100499340B1 (ko) *	2003-04-29	2005-07-04	학교법인 이화학당	암 조직 선택성과 생분해성을 갖는폴리포스파젠-백금(ⅱ)착물 복합체 항암제 및 그 제조방법
WO2006091790A1 (en) *	2005-02-23	2006-08-31	Xenoport, Inc.	Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
RU2319491C1 (ru)	2006-07-12	2008-03-20	Бадулин Николай Александрович	Противоопухолевая, антибактериальная и антивирусная фармацевтическая композиция (ее варианты)
US8389506B2 (en) *	2007-12-07	2013-03-05	Prana Biotechnology Ltd.	Compounds for therapy and diagnosis
ES2704303T3 (es)	2010-08-24	2019-03-15	Dana Farber Cancer Inst Inc	Procedimientos para la predicción de una respuesta contra el cáncer
ES2768344T3 (es)	2011-06-17	2020-06-22	Myriad Genetics Inc	Métodos y materiales para evaluar el desequilibrio alélico
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
CN103703011B (zh) *	2011-12-07	2016-06-22	北京市丰硕维康技术开发有限责任公司	一类离去基团是含氨基或烷氨基的羟基酸衍生物的铂类化合物及其制备方法和应用
JP6325453B2 (ja)	2011-12-21	2018-05-16	ミリアド・ジェネティックス・インコーポレイテッド	ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
ES2687024T3 (es)	2012-02-23	2018-10-23	Children's Medical Center Corporation	Procedimientos para predecir la respuesta contra el cáncer
CA2867434C (en)	2012-06-07	2021-10-12	Institut Curie	Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en)	2013-03-14	2019-06-04	Children's Medical Center Corporation	Cancer diagnosis, treatment selection and treatment
BR112015031278B1 (pt)	2013-06-14	2022-05-17	Akamara Therapeutics, Inc	Compostos e nanopartículas de platina com base em lipídio, seus processos de preparação, composições farmacêuticas compreendendo os mesmos e seus usos no tratamento de câncer
WO2014203691A1 (ja) *	2013-06-18	2014-12-24	株式会社ヤクルト本社	白金錯体を含有する新規医薬
CA2931181C (en)	2013-12-09	2023-01-24	Institut Curie	Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
DK3686288T3 (da)	2014-08-15	2023-05-22	Myriad Genetics Inc	Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
EP3297681B1 (de)	2015-05-19	2022-03-16	Akamara Therapeutics, Inc.	Verfahren zur herstellung supramolekularer platinbasierter verbindungen
US20210137874A1 (en) *	2017-03-22	2021-05-13	The Regents Of The University Of California	Modified platinum compounds and therapeutic uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4115418A (en) *	1976-09-02	1978-09-19	Government Of The United States Of America	1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity
US4284579A (en) *	1979-07-17	1981-08-18	The United States Of America As Represented By The Of The Department Of Health & Human Services	(N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt
JPS57123198A (en) *	1981-01-23	1982-07-31	Shionogi & Co Ltd	Novel platinum complex
JPS5921697A (ja) *	1982-06-24	1984-02-03	Yoshinori Kitani	新規な白金錯体
US4673754A (en) *	1983-10-14	1987-06-16	Inco Alloys International, Inc.	Platinum and palladium complexes
IL73337A (en) *	1984-10-28	1988-09-30	Yissum Res Dev Co	Antitumor steroid-platinum complexes and method for the preparation thereof
US4587331A (en) *	1984-12-17	1986-05-06	American Cyanamid Company	Platinum complexes of polyhydroxylated alkylamines and 2-polyhydroxylated alkyl-1,2-diaminoethanes
EP0284197A1 (de) *	1987-02-20	1988-09-28	Tanabe Seiyaku Co., Ltd.	Organische Platinkomplexe und Verfahren zu deren Herstellung
JP2749092B2 (ja) *	1987-07-17	1998-05-13	ジョージタウン・ユニバーシティー	白金系医薬品

1989
- 1989-01-26 US US07/301,773 patent/US4946954A/en not_active Expired - Fee Related
1990
- 1990-01-16 PH PH39898A patent/PH26424A/en unknown
- 1990-01-17 EP EP19900902930 patent/EP0462980A4/en not_active Withdrawn
- 1990-01-17 JP JP2503681A patent/JP2771326B2/ja not_active Expired - Lifetime
- 1990-01-17 ZA ZA90336A patent/ZA90336B/xx unknown
- 1990-01-17 WO PCT/US1990/000171 patent/WO1990008157A1/en not_active Ceased
- 1990-01-17 IL IL9309090A patent/IL93090A/en not_active IP Right Cessation
- 1990-01-17 HU HU901456A patent/HUT59690A/hu unknown
- 1990-01-17 CA CA002045120A patent/CA2045120A1/en not_active Abandoned
- 1990-01-17 RU SU905001256A patent/RU2074861C1/ru active
- 1990-01-17 NZ NZ232134A patent/NZ232134A/en unknown
- 1990-01-17 AU AU50394/90A patent/AU5039490A/en not_active Abandoned
1991
- 1991-07-11 NO NO912732A patent/NO180588C/no unknown
1994
- 1994-01-31 AU AU54792/94A patent/AU674185B2/en not_active Ceased

Also Published As

Publication number	Publication date
JPH04502767A (ja)	1992-05-21
NO180588B (no)	1997-02-03
HUT59690A (en)	1992-06-29
NZ232134A (en)	1992-09-25
AU5479294A (en)	1994-03-31
WO1990008157A1 (en)	1990-07-26
EP0462980A1 (de)	1992-01-02
IL93090A (en)	1995-10-31
CA2045120A1 (en)	1990-07-18
IL93090A0 (en)	1990-11-05
AU5039490A (en)	1990-08-13
NO912732L (no)	1991-07-11
RU2074861C1 (ru)	1997-03-10
AU674185B2 (en)	1996-12-12
NO912732D0 (no)	1991-07-11
US4946954A (en)	1990-08-07
JP2771326B2 (ja)	1998-07-02
ZA90336B (en)	1990-10-31
EP0462980A4 (en)	1992-03-11
NO180588C (no)	1997-05-14

Publication	Publication Date	Title
US4946954A (en)	1990-08-07	Platinum pharmaceutical agents
US5434256A (en)	1995-07-18	Diamine platinum complexes as antitumor agents
US4895936A (en)	1990-01-23	Platinum pharmaceuticals
EP0394262B1 (de)	1994-01-05	Platin-verbindungen, geeignet zur verwendung als arzneimittel
US4895935A (en)	1990-01-23	Platinum pharmaceuticals
EP0376959B1 (de)	1993-03-24	Platin-arzneimittel
HU203246B (en)	1991-06-28	Process for producing antitumoural platinum(iv)-diamine complex and pharmaceutical compositions comprising such compound as active ingredient
EP1968991B9 (de)	2012-08-08	Bisplatinkomplexe mit antitumorwirkung
EP0186085A2 (de)	1986-07-02	Platin-Komplexe
PT100272B (pt)	1999-09-30	Novo complexo de platina(ii) e processo para a sua preparacao
US5041579A (en)	1991-08-20	Platinum complexes and uses therewith
EP0214862B1 (de)	1991-03-13	Antitumor-Platinkomplexe, deren Herstellung und Verwendung
EP0518645B1 (de)	1997-01-15	Platin(II)-Komplex und Antitumormittel
US4999444A (en)	1991-03-12	Novel neutral mixed ligand platinum(II) and platinum(IV) complexes
CA1265811A (en)	1990-02-13	O-alkyl platinum diamine compounds
JPS61249993A (ja)	1986-11-07	新規有機白金錯体及びその製法